However, our results suggest that specific patients at higher genetic risk for HF (i.e., those with higher genetic liability to HF, plus higher genetically predicted body fat mass, lean mass, and lipoprotein A, and carrying the pharmacogenetic RYR3 variant rs877087 T-allele) have worse outcomes compared to those with lower genetic risk. The gene discussed is RYR3; the disease is hydrops fetalis.